Ethyl 2-(6-bromoimidazo[1,2-a]pyridin-3-yl)acetate

Catalog No. :
ACGWRD864
CAS No. :
603311-76-8
Molecular Formula :
C11H11BrN2O2
Molecular Weight :
283.13

IUPAC Name:ethyl 2-(6-bromoimidazo[1,2-a]pyridin-3-yl)acetate

Ethyl 2-(6-bromoimidazo[1,2-a]pyridin-3-yl)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$113.00Login to see priceIn stockInquiry
10g95%$177.00Login to see priceIn stockInquiry
25g95%$422.00Login to see priceInquiryInquiry
100g95%$1588.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEthyl 2-(6-bromoimidazo[1,2-a]pyridin-3-yl)acetate
IUPAC Nameethyl 2-(6-bromoimidazo[1,2-a]pyridin-3-yl)acetate
MDL No.MFCD09839780
Molecular FormulaC11H11BrN2O2
Molecular Weight283.13
SMILESO=C(OCC)CC1=CN=C2C=CC(Br)=CN21
InChI KeyNXSULFYVLBGQDA-UHFFFAOYSA-N
Synonym603311-76-8 | Ethyl 2-(6-bromoimidazo[1,2-a]pyridin-3-yl)acetate | ETHYL 2-(6-BROMOH-IMIDAZO[1,2-A]PYRIDIN-3-YL)ACETATE | ethyl 2-{6-bromoimidazo[1,2-a]pyridin-3-yl}acetate | Ethyl 2-(6-bromo-imidazo[1,2-a]pyridin-3-yl)acetate | ETHYL 6-BROMOIMIDAZO[1,2-A]PYRIDINE-
CAS No.603311-76-8
PubChem CID46839968

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACGWRD864 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTRMX927 route compound structure diagram
    ACTRMX927555-75-9
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGWRD864 route product structure diagram
    ACGWRD864603311-76-8 In Stock
Inquiry

2. ACGWRD864 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGWRD864 route product structure diagram
    ACGWRD864603311-76-8 In Stock
Inquiry

Comments (0)